human liver disease
Recently Published Documents


TOTAL DOCUMENTS

92
(FIVE YEARS 9)

H-INDEX

30
(FIVE YEARS 2)

Hepatology ◽  
2021 ◽  
Author(s):  
Philipp Königshofer ◽  
Benedikt Silvester Hofer ◽  
Ksenia Brusilovskaya ◽  
Benedikt Simbrunner ◽  
Oleksandr Petrenko ◽  
...  

2021 ◽  
Vol 118 (10) ◽  
pp. e2025242118
Author(s):  
Pasquale Piccolo ◽  
Rosa Ferriero ◽  
Anna Barbato ◽  
Sergio Attanasio ◽  
Marcello Monti ◽  
...  

α1-Antitrypsin (AAT) deficiency is a common genetic disease presenting with lung and liver diseases. AAT deficiency results from pathogenic variants in the SERPINA1 gene encoding AAT and the common mutant Z allele of SERPINA1 encodes for Z α1-antitrypsin (ATZ), a protein forming hepatotoxic polymers retained in the endoplasmic reticulum of hepatocytes. PiZ mice express the human ATZ and are a valuable model to investigate the human liver disease of AAT deficiency. In this study, we investigated differential expression of microRNAs (miRNAs) between PiZ and control mice and found that miR-34b/c was up-regulated and its levels correlated with intrahepatic ATZ. Furthermore, in PiZ mouse livers, we found that Forkhead Box O3 (FOXO3) driving microRNA-34b/c (miR‐34b/c) expression was activated and miR-34b/c expression was dependent upon c-Jun N-terminal kinase (JNK) phosphorylation on Ser574. Deletion of miR-34b/c in PiZ mice resulted in early development of liver fibrosis and increased signaling of platelet-derived growth factor (PDGF), a target of miR-34b/c. Activation of FOXO3 and increased miR-34c were confirmed in livers of humans with AAT deficiency. In addition, JNK-activated FOXO3 and miR-34b/c up-regulation were detected in several mouse models of liver fibrosis. This study reveals a pathway involved in liver fibrosis and potentially implicated in both genetic and acquired causes of hepatic fibrosis.


Oncotarget ◽  
2020 ◽  
Vol 11 (23) ◽  
pp. 2216-2232 ◽  
Author(s):  
Aejaz Sayeed ◽  
Brielle E. Dalvano ◽  
David E. Kaplan ◽  
Usha Viswanathan ◽  
John Kulp ◽  
...  

2019 ◽  
Vol 3 (4) ◽  
pp. 040902 ◽  
Author(s):  
Gregory H. Underhill ◽  
Salman R. Khetani

JHEP Reports ◽  
2019 ◽  
Vol 1 (5) ◽  
pp. 392-402 ◽  
Author(s):  
Michele Alves-Bezerra ◽  
Nika Furey ◽  
Collin G. Johnson ◽  
Karl-Dimiter Bissig

Molecules ◽  
2019 ◽  
Vol 24 (20) ◽  
pp. 3642
Author(s):  
Liangcai Lin ◽  
Huanyu Guan ◽  
Rui Li ◽  
Xiangming Liao ◽  
Feifei Zhao ◽  
...  

Acetaminophen (APAP) overdose is very common worldwide and has been widely recognized as the leading cause of drug-induced liver injury in the Western world. In our previous investigation, auriculatone, a natural product firstly obtained from Aster auriculatus, has demonstrated a potent protective effect against APAP-induced hepatotoxicity in HL-7702 cells. However, the poor water solubility and low bioavailability restrict its application. Auriculatone sulfate (AS) is a sulfated derivative of auriculatone with highly improved water-solubility. Hepatoprotective effects against APAP-induced liver injury (AILI) showed that intragastric pretreatment with AS at 50 mg/kg almost completely prevented mice against APAP-induced increases of serum alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and ATPase. Histological results showed that AS could protect the liver tissue damage. In addition, AS pretreatment not only significantly retained hepatic malondialdehyde and the activities of glutathione, superoxide dismutase, and glutathione peroxidase at normal levels, but also markedly suppressed the increase of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 levels in mouse liver caused by overdose APAP. Immunohistochemical analysis showed that AS obviously attenuated the expression of CD45 and HNE in liver tissue. Further mechanisms of action investigation showed that inhibition of cytochrome P450 3A11 (CYP 3A11) and CYP2E1 enzymatic activities (but not that of CYP1A2) was responsible for APAP bioactivation. In conclusion, AS showed a hepatoprotective effect against AILI through alleviating oxidative stress and inflammation and inhibiting CYP-mediated APAP bioactivation. It may be an effective hepatoprotective agent for AILI and other forms of human liver disease.


2019 ◽  
Vol 156 (6) ◽  
pp. S-452
Author(s):  
Tien S. Dong ◽  
Venu Lagishetty ◽  
Kayti Luu ◽  
Meg Hauer ◽  
William Katzka ◽  
...  

Gut ◽  
2018 ◽  
Vol 68 (11) ◽  
pp. 2097-2100 ◽  
Author(s):  
Miya John ◽  
Kyung-Jin Kim ◽  
Sarah Da Won Bae ◽  
Liang Qiao ◽  
Jacob George

Sign in / Sign up

Export Citation Format

Share Document